PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801RYK" target="_blank" >RIV/61988987:17110/17:A1801RYK - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/16:E0106005

Výsledek na webu

<a href="http://dx.doi.org/10.1080/2162402X.2016.1254856" target="_blank" >http://dx.doi.org/10.1080/2162402X.2016.1254856</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/2162402X.2016.1254856" target="_blank" >10.1080/2162402X.2016.1254856</a>

Jazyk výsledku

angličtina

Název v původním jazyce

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

Popis výsledku v původním jazyce

The introduction of PD-1/PD-L1 pathway inhibitors has marked a significant milestone in the treatment of various types of solid tumors. The current situation in multiple myeloma ( MM) is rather unclear, as distinct research groups have reported discordant results. This discrepancy dominantly concerns the expression of PD-1/PD-L1 molecules as well as the identification of the responsible immune effector cell population. The results of monotherapy with PD-1/PD-L1 inhibitors have been unsatisfactory in MM, suggesting that a combination approach is needed. The most logical partners are immunomodulatory agents as they possess many synergistic effects. We are also proposing other rational and promising combinations (e.g., daratumumab, ibrutinib, anti-CD137) that warrant further investigation.

Název v anglickém jazyce

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

Popis výsledku anglicky

The introduction of PD-1/PD-L1 pathway inhibitors has marked a significant milestone in the treatment of various types of solid tumors. The current situation in multiple myeloma ( MM) is rather unclear, as distinct research groups have reported discordant results. This discrepancy dominantly concerns the expression of PD-1/PD-L1 molecules as well as the identification of the responsible immune effector cell population. The results of monotherapy with PD-1/PD-L1 inhibitors have been unsatisfactory in MM, suggesting that a combination approach is needed. The most logical partners are immunomodulatory agents as they possess many synergistic effects. We are also proposing other rational and promising combinations (e.g., daratumumab, ibrutinib, anti-CD137) that warrant further investigation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ONCOIMMUNOLOGY

ISSN

2162-402X

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

000392846200038

EID výsledku v databázi Scopus

2-s2.0-85007452270